title: Does protein binding modulate the effect of angiotensin II receptor antagonists?
abstract: Introduction Angiotensin II AT 1-receptor antagonists are highly bound to plasma proteins (≥ 99%). With some antagonists, such as DuP-532, the protein binding was such that no efficacy of the drug could be demonstrated clinically. Whether protein binding interferes with the efficacy of other antagonists is not known. We have therefore investigated in vitro how plasma proteins may affect the antagonistic effect of different AT1-receptor antagonists. Methods A radio-receptor binding assay was used to analyse the interaction between proteins and the ability of various angiotensin II (Ang II) antagonists to block AT1-receptors. In addition, the Biacore technology, a new technique which enables the real-time monitoring of binding events between two molecules, was used to evaluate the dissociation rate constants of five AT1-receptor antagonists from human serum albumin. Results The in vitro AT 1-antagonistic effects of different Ang II receptor antagonists were differentially affected by the presence of human plasma, with rightward shifts of the IC50 ranging from one to several orders of magnitude. The importance of the shift correlates with the dissociation rate constants of these drugs from albumin. Our experiments also show that the way that AT1-receptor antagonists bind to proteins differs from one compound to another. These results suggest that the interaction with plasma proteins appears to modulate the efficacy of some Ang II antagonists. Conclusion Although the high binding level of Ang II receptor antagonist to plasma proteins appears to be a feature common to this class of compounds, the kinetics and characteristics of this binding is of great importance. With some antagonists, protein binding interferes markedly with their efficacy to block AT1-receptors.
authors.affiliation: Division of Hypertension and Vascular Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland, Marc.Maillard@chuv.hospvd.ch.
authors.forename: Marc P
authors.initials: MP
authors.lastname: Maillard
authors.affiliation: Division of Hypertension and Vascular Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland.
authors.forename: Catherine
authors.initials: C
authors.lastname: Centeno
authors.affiliation: Biacore AB, S-754 50 Uppsala, Sweden.
authors.forename: Åsa
authors.initials: Å
authors.lastname: Frostell-Karlsson
authors.affiliation: Division of Hypertension and Vascular Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland.
authors.forename: Hans R
authors.initials: HR
authors.lastname: Brunner
authors.affiliation: Division of Hypertension and Vascular Medicine, Lausanne University Hospital, CH-1011 Lausanne, Switzerland.
authors.forename: Michel
authors.initials: M
authors.lastname: Burnier
keywords: AT1-receptor antagonists; pharmacokinetic; protein binding